Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Blood-testing start-up Theranos took a number of management missteps that led to its most recent tangle with health regulators, business school professors said Thursday on CNBC's "Power Lunch. "
For several months, federal health regulators have raised concerns about the accuracy of the company's blood-testing technology. On Wednesday, The Wall Street Journal reported that the Centers for Medicare and Medicaid Services threatened to impose stiff sanctions on the company — including a ban that could prohibit Theranos CEO Elizabeth Holmes from owning or running a lab for at least two years.
In an interview with CNBC, Theranos spokesperson Brooke Buchanan stressed that the company is actively working to address issues raised by regulators.
"Elizabeth Holmes has not been banned from the industry, she hasn't been banned from Theranos and we continue to work hard to address all the concerns that have been raised by CMS," Buchanan said. "We're in constant communication with the regulators."
News of the potential sanctions against Theranos was not surprising, Bill George, a Harvard Business School professor and CNBC contributor, said on "Power Lunch."
"Theranos has never been forthcoming about its test results," George said.
There were other warning signs, too, said Jeff Sonennfeld, senior associate dean of the Yale School of Management.
"They've gone through some traumatic changes in board governance," Sonnenfeld said, noting that the company at one point counted former U.S. Sen. Bill Frist, former Secretary of State George Shultz, and Henry Kissinger as board members.
Any sanction CMS decides to impose on Theranos would likely meet a lengthy appeal process, the Journal reported Wednesday.
If Theranos is ultimately sanctioned, however, it could spell out the company's demise, George said.
"This is very, very serious," he said.